Tech Company Financing Transactions
Immuneering Funding Round
On 12/17/2019, Immuneering landed $17 million in Series A funding from Boxcar PMJ and private investors.
Transaction Overview
Company Name
Announced On
12/17/2019
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Series A
Investors
Boxcar PMJ (Lead Investor)
Proceeds Purpose
The company plans to use the proceeds to advance its lead program in cancer cachexia and its pipeline of oncology medicines driven by its Disease Cancelling Technology (DCT), develop its technology platforms, launch new drug programs in other disease areas and support the growth of its computational biology services business.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
245 Main St. 2nd Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Immuneering leverages more than a decade of leadership in bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods. Its current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 12/17/2019: Garwood Medical Devices venture capital transaction
Next: 12/17/2019: Gecko Robotics venture capital transaction
Share this article
Where The Data Comes From
We document all VC transactions involving tech companies. VC investment data records on this site come from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs